Company intelligence / Profile preview

Omrix

Ownership: Private
Employees: ~281
Development stage: Commercial

Overview

Omrix has developed and commercialized several protein-based biosurgical products for surgical bleeding control and passive immunotherapy. Its lead products include EVICEL® Fibrin Sealant and EVARREST® Fibrin Sealant Patch. These have been recognized for innovation in surgical hemostasis and are distributed globally through Johnson & Johnson’s ETHICON division. The company also developed antibody-rich plasma-derived therapies.

Therapeutic areas: Infectious DiseasesImmunologyHematology
Modalities: BiologicProtein-based therapy
Industry: Surgical Medical Devices

Drug pipeline

3 assets

EVITHROM

Commercial

Indications: Surgical bleeding

2 more assets in the full pipeline.

Request access →

Partnerships

ETHICON/Johnson & Johnson—exclusive distribution rights in US/EU for key productshistorical collaborations with other pharma companies on marketing/sales

Beyond the preview

Go deeper on Omrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omrix.

Explore the full profile